2015
HER2 as Biomarker for Endometrial Cancer
English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. Biomarkers In Disease: Methods, Discoveries And Applications 2015, 507-526. DOI: 10.1007/978-94-007-7681-4_26.ChaptersEndometrial cancerEpidermal growth factor (EGF) familyGrowth factor familyC-erbB2 geneFactor familyCell survivalErbB pathwayNovel tyrosine kinase inhibitorOverall poor survivalOverexpression of HER2Tyrosine kinase inhibitorsKinase inhibitorsEndometrial neoplasmsPoor survivalPathwayTumor typesHER2Monoclonal antibodiesCancerGenesBiomarkersOverexpressionSurvivalWide varietyErbB2
2014
HER2 as Biomarker for Endometrial Cancer
English D, Roque D, Buza N, Santin A. HER2 as Biomarker for Endometrial Cancer. 2014, 1-16. DOI: 10.1007/978-94-007-7744-6_26-1.ChaptersEndometrial cancerEpidermal growth factor (EGF) familyGrowth factor familyC-erbB2 geneFactor familyCell survivalErbB pathwayNovel tyrosine kinase inhibitorOverall poor survivalOverexpression of HER2Tyrosine kinase inhibitorsKinase inhibitorsEndometrial neoplasmsPoor survivalPathwayTumor typesHER2Monoclonal antibodiesCancerGenesBiomarkersOverexpressionSurvivalWide varietyErbB2
2013
HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
English DP, Roque DM, Santin AD. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Molecular Diagnosis & Therapy 2013, 17: 85-99. PMID: 23529353, PMCID: PMC3660991, DOI: 10.1007/s40291-013-0024-9.Peer-Reviewed Original ResearchConceptsAggressive neoplasmCytotoxic chemotherapy agentsOverall poor survivalTyrosine kinase inhibitorsEpidermal growth factor (EGF) familyGrowth factor familyGynecologic malignanciesEndometrial cancerHER2 expressionClinical trialsOvarian cancerPoor survivalBreast cancerChemotherapy agentsC-erbB2 geneTherapeutic implicationsTumor typesHER2Monoclonal antibodiesSubset of breastKinase inhibitorsCancerNeoplasmsCell survivalBreast